Pacific Biosciences (PACB) Stephens Annual Investment Conference summary

Industry trends and market dynamics

• Long read sequencing is gaining traction due to recent data showing it detects more structural variants than short read, with studies like All of Us and HiFi consortium highlighting significant advantages for discovery and diagnosis.

• Cost has been a major barrier, but new chemistry (Spark Next) is bringing long read sequencing close to cost parity with short read, enabling broader adoption and interest from previously inaccessible customer segments.

• Clinical applications, especially in rare disease and carrier testing, are driving adoption, with clinics like Radboud fully converting to long read for diagnostics.

• Software and data infrastructure are evolving, with a focus on enriching existing short read datasets using long read data and leveraging AI for deeper insights.

• Collaboration and competition with other long read providers, such as Oxford, are seen as synergistic, with each company excelling in different application areas.

Product development and adoption

• A complete end-to-end product portfolio has been developed, addressing previous barriers to long read adoption, including sample prep, chemistry, and software.

• Spark and Spark Next chemistries have reduced sample requirements and costs, making long read more accessible and increasing throughput.

• New instruments like Revio and Vega are attracting both new and existing customers, with about 60% of recent shipments going to first-time long read users.

• Vega serves as an entry point for smaller labs and is expected to feed demand for higher-throughput Revio systems as customer needs grow.

• Strategic discounting has been used for key accounts with high utilization potential, but average selling prices are expected to normalize.

Financial outlook and operational strategy

• Consumable mix is the primary driver for gross margin improvement, with clinical accounts offering more predictable and higher utilization.

• Production efficiencies for Revio and Vega are improving as both move to full-scale manufacturing, reducing unit costs.

• Operating expenses are being tightly controlled, with guidance for 2026 OpEx to be lower than 2025, supporting the goal of cash flow positivity by end of 2027.

• The Spark Next launch and increased clinical penetration are seen as key levers for top-line growth and margin expansion.

• Early access and beta programs are being used to manage the rollout of new chemistries and ensure quality and utilization before full release.